Referenser

  1. Timmer CJ, Houwing NS. Dose proportionality of three different doses of tibolone. Pharmacotherapy 2002; 22: 6-13
  2. Vos RM, Krebbers S, Verhoeven C, Delbressine L. In vivo human metabolism of tibolone. Drug Metab Dispos 2002; 30: 106-122
  3. Verhoeven C, Vos RM, Delbressine L. The in vivo metabolism of tibolone in several animal species. Eur J Drug Metab Pharmacokinetics 2002; 27: 1-10
  4. McLintock LA, Dykes A, Tait RC, Walker ID. Interaction between hormone replacement therapy preparations and oral anticoagulant therapy.
    BJOG 2003; 110: 777-779
  5. Timmer CJ, Huisman JAM. The effect of a standardized meal on the bioavailability of a single oral dose of 2.5 mg of tibolone in healthy early postmenopausal women. Pharmacotherapy 2002; 22: 310-315
  6. Markiewicz L, Gurpride E. In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990; 35: 535-541
  7. Gooyer ME de, Deckers GH, Schoonen WGEJ, Verheul HAM, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone.
    Steriods 2003; 68: 21-30
  8. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int. 1994; 4: 314-319
  9. Ederveen AGH, Spanjers CPM, Qauijtaal JHM, Kloosterboer HJ. Effect of 16 months of treatment with tibolone on bone mass, turnover and biomechanical qualtiry in mature ovarieectomised rats. J Bone Miner Res 2001; 16: 1674-1681
  10. Ederveen AGH, Kloosterboer HJ. Tibolone exerts its protective effect on trabecualr bone loss through the estrogen receptor.
    J Bone Miner Res 2001; 16: 1651-1657
  11. de Gooyer ME, Overklift Vaupel Kleyn GT, Smits KC, Ederveen AGH, Verheul HAM, Kloosterboer HJ. Tibolone a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001; 183: 55-62
  12. de Gooyer ME, Oppers-Tiemissen HM, Leysen D, Verheul HAM, Kloosterboer HJ. Tibolone is not converted by human aromatase to 7 a -methyl-17 a -ethynyl-estradiol (7 a -MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 2003; 68: 235-243
  13. Kloosterboer HJ. New mechanisms of action for tibolone in breast cancer.
    Neves-e-Castro M, Wren BG (eds.) eds. In: Menopause Hormones and Cancer. New York: Pathenon, 2003: pp 37-47
  14. Tang B, Markiewicz L, Kloosterboer HJ, Gurpride E. Human endometrial
    3b-hydroxysteroid dehydrogenase/isomerase can locally reduce the intrinsic estrogenic/progestogenic activity ratios of steroidal drugs.
    J Steroid Biochem Mol Biol 1993; 45: 345-351
  15. Hänggi W Et al. Comparison of transvaginal ultrasonography and endometrial surveillance in postmenopausal HRT users. Maturitas 1997; 27: 133-143.
  16. Gregoriou O et al. Effect of tibolone on postnenopausal women with myomas. Maturitas 1997; 27: 187-91
  17. Landgren MB, Coelingh Bennink HJT, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms.
    Br J Obstet Gynaecol 2002; 109: 1109-1114
  18. Helmond FA, Coelingh Bennink HJT, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms in highly symptomatic subjects with at least seven hot flushes and sweats/day. In: Abstracts and posters on Livial (tibolone): 9th International Menopause Symposium, October 17-21, 1999, Yokohama, Japan. Oss: Organon: 1999: 1:
  19. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904-911
  20. Baracat EC, Barbosa IC, Giordano MG, Haidar MA, Marinho RM, Menegocci JC, Morais KM, Tomaz G, Wehba S. A randomized, open-label study of conjugated equine estrogens plus edroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Climacteric 2002; 5: 60-69
  21. Genazzani AR, Petraglia F, Facchinetti F, Genazzani AD, Bergamaschi M, Grasso O, Volpe A. Effcts of org OD 14 on pituitary and peripheral beta-endorphin in castrated rats and in postmenopausal women.
    Maturitas 1987; 1: 35-48
  22. Davis SR. The effects of tibolone on mood and libido.
    Menopause 2002; 9: 162-170
  23. Tax L, Goorissen EM, Kicovic PM. Clinical profile of Org OD 14.
    Maturitas 1987; 1: 3-13
  24. Egarter CH, Huber J, Leikermoser R, Haidbauer R, Pusch H, Fischl F, Putz M. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996; 23: 55-62
  25. Rymer J, Chapman MG, Fogelman I. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994; 18: 127-133
  26. Punnonen R, Liukko P, Cortes-Prieto J. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in psot-menopausal and oophorectomised women. Maturitas 1984; 5: 281-286
  27. Morris EP, Wilson POG, Robinson J, Rymer JM. Long-term effects of tibolone on the genital tract in postmenopausal women.
    Br J Obstet Gynaecol 1999; 106: 954-959
  28. Morris EP, Chong H, Robinson J, Bruce D, Rymer JM. Effects on the lower genital tract of tibolone use for 8 years in postmenopausal women.
    Maturitas 2000; 35 Suppl. 1: 50
  29. Lindsay R, McHart D, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis.
    BMJ 1980; 280: 1207-1209
  30. Lyritis GP, Karpathios S, Basdekis K, Grigoriu O, Katostaras T, Paspati I, Stamatopoulos T, Siampalioti G, Lyritis PG. Prevention of post-oophorectomy bone loss with tibolone. Maturitas 1995; 22: 247-253
  31. Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral denstity induced by synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991; 13: 155-162
  32. Stepán JJ, Schreiber V. Anabolic effects of progestogens in bone remodelling. Sbornik Lekarsky 1995; 96: 293-297
  33. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone prevention of bone loss in late postmenopausal women.
    J Clin Endocrinol Metab 1996; 81: 2419-2422
  34. Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BCJM. Effects of two doses of tibolone on trabecular and corticoid bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study.
    Bone 1996; 19: 395-399
  35. Prelevic GM, Bartram C, Wood J, Okolo S, Ginsburg J. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in psotmenopausal women.
    Gynecol Endocrinol 1996; 10: 413-420
  36. Bjarnason NH, Bjarnason K, Hassager C, Christiansen C. The response in spinal bone mass to tibolone treatment is related to boen turnover in elderly women. Bone 1997; 20: 151-155
  37. Lippuner K, Haenggi W, Birkhauser MH, Casez J-P, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-oestradiol and dydrogesterone.
    J Bone Min Res 1997; 12: 806-812
  38. Studd J, Arnala I, Kicovic PM, Zamblera D, Kröger H, Holland N. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92: 574-579
  39. Pavlov PW, Ginsburg J, Kicovic PM, van der Scaaf DB, Prelevic G, Coelingh Bennink HJT. Double-blind, placebo controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol Endocrinol 1999; 13: 230-237
  40. Beardsworth SA, Kearney CE, Purdie DW. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. Br J Obstet Gynaecol 1999; 13: 230-237
  41. Rymer J, Robinson J, Fogelman I. Effect of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int 2001; 12: 478-483
  42. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-findings studies.
    J Clin Endocrinol Metab 2001; 86: 4717-4726
  43. Milner M, Harrison RF, Gilligan E, Kelly A. Bone density changes during 2 years treatmetn with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause 2000; 7: 327-333
  44. Thiébaud D, Bigler JM, Renteria S, Pache T, Welti AJ, Landry M, Burckhardt P. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
    Menopause Sonderheft 1999; 1: 19-26
  45. Rymer J. 10 Years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 2002; 5: 390-398
  46. Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-blind, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis Int 2002; 13: 241-248
  47. Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan H, Christau S, Helmond F. The effect of tibolone compared with conjugated equine estrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women.
    Br J Obstet Gynaecol 2002; 109: 886-893
  48. Lundström E, Christow A, Svane G, Kersemaekers W, Azavedo E, Söderqvist G, Mol M, Barkfeldt J, Schoultz B von. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density.
    Am J Obstet Gynecol 2002; 186: 717-722
  49. Dören M, Rübig A, Coelingh Bennink HJT, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy.
    Menopause 1999; 6: 299-306
  50. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJT. Effect of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study.
    Fertil Steril 2000; 74: 10-19
  51. Lehman CD, White E, Peacock S, Drucker MJ, Urban N. Effect of age and breast density on screening mammograms with false-positive findings.
    AJR Am J Roentgenol 1999; 173: 1651-1655
  52. Lundström E, Christow A, Svane G, Kersemaekers W, Azavedo E, Söderqvist G, Mol M, Barkfeldt J, Schoultz B von. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density.
    Am J Obstet Gynecol 2002; 186: 717-722
  53. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy.
    Clin Drug Invest 2000; 20: 101-107
  54. Colacurci N, Fornaro F, Franciscis P de, Palermo M, Vecchio E del. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001; 40: 159-164
  55. Sendag F, Cosan Terek M, Ozsener S, Oztekin K, Bilgin O, Bilgen I, Memis A. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001; 76: 445-450
  56. Erel CT, Esen G, Seyisoglu H, Elter K, Uras C, Ertungealp E, Aksu MF. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001; 40: 151-157
  57. Valdivia I, Campodonico I, Tapia A, Capetillo M, Espinoza A, Lavin P. Related Articles, Links. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004 Mar;81(3):617-23
  58. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KPC, Kelekis DA, Creatsas G. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study.
    Menopause 2002; 9: 110-116
  59. Sendag F, Terek MC, Özsener S, Öztekin K. Mammographic density changes in postmenopausal women using tibolone therapy.
    Int J Gynecol Obstet 2001; 74: 63-64
  60. Erel CT, Elter K, Akman C, Ersavasti G, Altug A, Seyisoglu H, Ertungealp E. Mammographic changes in women receiving tibolone therapy.
    Fertil Steril 1998; 69: 870-875
  61. Kutlu T, Ficicioglu C, Basaran T, Basaran E, Topaloglu T. Related Articles, Links. Mammographic breast density changes after 1 year of tibolone use.
    Maturitas. 2004 Jun 15;48(2):133-6
  62. Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts.
    Maturitas 2001; 40: 165-171
  63. Schoultz B von. The effects of tibolone and conventional HRT in breast cell proliferation and mammographic density. Climacteric 2002; 5 (Suppl 1): 216
  64. Milion Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427
  65. Allen DS, de Vries CS, Farmer RDT. Pharmaceutical content and regimen of hormone replacement therapy and risk of breast cancer.
    Pharmacoepidemiol Drug Saf 2002; 11 (Suppl 1): 296
  66. Phillips CJ. Livial: an economic appraisal.
    Br J Obstet Gynaecol 1999; supp19: 22-28
  67. Plumb JM, Guest JF. Economic impact of tibolone compared with continuous-combined hormone replacement therapy in the management of postmenopausal women with climacteric symptoms in the UK.
    Pharmacoeconomics 2000; 18:477-486

univadis.se

Rapport från "12th World Congress of Gynecological Endro-crinology"

Florence, Italien, 2-5 mars 2006

Sagt från SFOG

Läs referat från Organons frukostsymposium på SFOG 2006. Ingen lust! Testosteron? med leg läk och med dr Angelique Flöter Rådestad från Kvinnokliniken, Karolinska Universitetssjukhuset.